Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Aug 15, 2017
CAMBRIDGE, Mass., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced a leadership transition plan for its finance organization. Andrew E. Singer, executive vice president, finance and administration and chief financial officer of Epizyme, w...
Aug 4, 2017
Key Clinical Milestones Achieved in Studies of Mesothelioma, Epithelioid Sarcoma and Pediatric Solid Tumors Expansion of Collaborations to Accelerate Investigation of Tazemetostat Across Multiple Tumor Types Conference Call to be Held Today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 04, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a c...
Aug 1, 2017
THE WOODLANDS, Texas and CAMBRIDGE, Mass., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, and US Oncology Research, one of the nation's largest networks of independent, community-based oncology practices dedicated to advancing high-quality treatments t...
Jul 31, 2017
CAMBRIDGE, Mass., July 31, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call in conjunction with the announcement of its second quarter 2017 financial results and present at the 2017 Wedbush PacGrow Healt...
Jul 24, 2017
CAMBRIDGE, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the National Cancer Institute (NCI), part of the National Institutes of Health, has initiated its NCI-COG Pediatric MATCH study, which includes a phase 2 evaluation o...
Jun 26, 2017
Tazemetostat and Atezolizumab to be Evaluated as New Combination in Study of Non-Small Cell Lung Cancer as Part of Genentech's MORPHEUS Cancer Immunotherapy Platform Further Expands Tazemetostat Solid Tumor Program CAMBRIDGE, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company cre...
Jun 21, 2017
CAMBRIDGE, Mass., June 21, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to tazemetostat, the company's first-in-class EZH2 inhibitor, for the treatment of pat...
Jun 14, 2017
Data Presented During Plenary Session at International Conference on Malignant Lymphoma Conference Call to be Held Today at 10:30 a.m. ET CAMBRIDGE, Mass., June 14, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced positive interim efficacy ...
May 18, 2017
Path Toward Submission for Accelerated Approval Tazemetostat Demonstrates Clinically Meaningful Activity in Epithelioid Sarcoma; Interim Phase 2 Epithelioid Sarcoma and Synovial Sarcoma Data to be Presented at ASCO Conference Call to be Held Today, May 18 at 8:30 a.m. ET CAMBRIDGE, Mass., May 18, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (N...
May 8, 2017
Interim Phase 2 Data of Tazemetostat in Molecularly Defined Solid Tumors and NHL to be Presented at Scientific Meetings in June Conference Call on Interim Solid Tumor Data to be Held on May 18, 2017 Conference Call on Interim NHL Data to be Held on June 14, 2017 CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM)...
May 4, 2017
CAMBRIDGE, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced it has earned a $10 million milestone payment from GlaxoSmithKline (GSK). The milestone payment follows GSK's initiation of GLP toxicology studies for a first-in-class meth...
Apr 25, 2017
Interim Efficacy and Safety Data from Ongoing Phase 2 Study in Follicular Lymphoma and DLBCL Selected for Plenary Presentation at the International Conference on Malignant Lymphoma Management to Host Conference Call on June 14 at 10:30 a.m. ETCAMBRIDGE, Mass., April 25, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage bi...
Apr 20, 2017
CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company will release its first quarter 2017 financial results on Monday, May 8, 2017. Epizyme also announced that two posters on interim efficacy and safety...
Mar 29, 2017
CAMBRIDGE, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that new preclinical data on tazemetostat, Epizyme's lead product candidate and first-in-class EZH2 inhibitor, along with other epigenetic target identification efforts, ...
Mar 9, 2017
Data from Tazemetostat Phase 2 Programs in NHL and Molecularly Defined Solid Tumors Planned for Medical Meetings in Second Quarter Conference Call to Be Held Today at 8:30 a.m. Eastern Time CAMBRIDGE, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic t...
Page:
...
Next Last
 
= add release to Briefcase